Surufatinib Administration: Surufatinib as monotherapy or combination therapy, at the discretion of the investigator based on the patient's overall condition.
Study summary
Prior clinical trials have demonstrated promising efficacy and manageable safety of surufatinib in neuroendocrine tumors (NETs). This real-world study aims to evaluate the clinical efficacy and safety of surufatinib in patients with NETs, providing additional real-world evidence to support clinical application, guide novel therapeutic strategies, and ultimately improve patient outcomes.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patients with pathologically or cytologically confirmed neuroendocrine tumors;
* At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1;
* Life expectancy ≥ 12 weeks;
* Adequate organ and bone marrow function
Exclusion Criteria:
* Participation in other drug clinical trials with investigational drug treatment within the past 4 weeks;
* History of other malignancies within the past 5 years, except for curatively resected basal cell or squamous cell carcinoma of the skin, or cervical carcinoma in situ;
* Patients with contraindications to surufatinib (e.g., active bleeding, ulcer, intestinal perforation, intestinal obstruction, medically uncontrolled hypertension, grade III-IV cardiac dysfunction, within 30 days after major surgery, severe hepatic or renal impairment, etc.);
* Presence of any disease or condition that affects drug absorption, or inability to take surufatinib orally;
* Any condition deemed by the investigator as unsuitable for study drug treatment.
Primary outcome measure(s)
Progression-free survival (PFS) — approximately up to 24 months the time from the date of first study treatment to the date of first documented tumor progression (assessed according to RECIST version 1.1) or death due to any cause, whichever occurs first.
Trial sites (1)
Facility
City
Region
Status
The First Affiliated Hospital of Xiamen University
Xiamen
Fujian
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.